Uveitis treatment trials-A cross-study perspective

Emmett T. Cunningham; Debra A. Goldstein; Manfred Zierhut

doi:10.3109/09273948.2012.661297

Uveitis treatment trials-A cross-study perspective

Emmett T. Cunningham^*, Debra A. Goldstein, Manfred Zierhut

^*Corresponding author for this work

Ophthalmology

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	63-67
Number of pages	5
Journal	Ocular Immunology and Inflammation
Volume	20
Issue number	2
DOIs	https://doi.org/10.3109/09273948.2012.661297
State	Published - Apr 2012

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

Access to Document

10.3109/09273948.2012.661297

Cite this

@article{7740ae5f886848459fe7d7fcff0be1cf,

title = "Uveitis treatment trials-A cross-study perspective",

author = "Cunningham, {Emmett T.} and Goldstein, {Debra A.} and Manfred Zierhut",

note = "Funding Information: Supported in part by The Pacific Vision Foundation (ETC), The San Francisco Retina Foundation (ETC), and an unrestricted grant from Research to Prevent Blindness, New York, NY, USA (DAG). We thank Nisha R. Acharya, John H. Kempen, and James T. Rosenbaum for thoughtfully reading and commenting on an early version of this editorial. Three and six month response rates and three, six, nine, and twelve month confidence intervals for the MUST Trial arms provided by Elizabeth Sugar, PhD on behalf of the Must Trial Research Group.",

year = "2012",

month = apr,

doi = "10.3109/09273948.2012.661297",

language = "English (US)",

volume = "20",

pages = "63--67",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - Uveitis treatment trials-A cross-study perspective

AU - Cunningham, Emmett T.

AU - Goldstein, Debra A.

AU - Zierhut, Manfred

N1 - Funding Information: Supported in part by The Pacific Vision Foundation (ETC), The San Francisco Retina Foundation (ETC), and an unrestricted grant from Research to Prevent Blindness, New York, NY, USA (DAG). We thank Nisha R. Acharya, John H. Kempen, and James T. Rosenbaum for thoughtfully reading and commenting on an early version of this editorial. Three and six month response rates and three, six, nine, and twelve month confidence intervals for the MUST Trial arms provided by Elizabeth Sugar, PhD on behalf of the Must Trial Research Group.

PY - 2012/4

Y1 - 2012/4

UR - http://www.scopus.com/inward/record.url?scp=84858209337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858209337&partnerID=8YFLogxK

U2 - 10.3109/09273948.2012.661297

DO - 10.3109/09273948.2012.661297

M3 - Review article

C2 - 22360435

AN - SCOPUS:84858209337

SN - 0927-3948

VL - 20

SP - 63

EP - 67

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 2

ER -

Uveitis treatment trials-A cross-study perspective

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this